| Product | Indication | Dosage form | Strength |
|---|---|---|---|
| Ethosuximide | Epilepsy, absence seizures | Soft capsules | 250 mg |
| Ethosuximide | Epilepsy, absence seizures | Oral solution | 50 mg/ml |
| Fampridine | Multiple sclerosis | XR tablets | 10 mg |
| Fingolimod | Multiple sclerosis | Capsules | 0.5 mg |
| Fluconazol | Antifungal | Hard capsules | 50, 100, 150 and 200 mg |
| Fluconazol | Antifungal | Powder for oral suspension | 200 mg/5ml and 50 mg/5ml |
| Hypromellose - Artificial tears | Dry eye | Eye drops, solution | 0.5 ml (unit dose) |
| Imidapril * | Hypertension | Tablets | 5, 10 and 20 mg |
| Irbesartan | Hypertension | Film-coated tablets | 75, 150 and 300 mg |
| Irbesartan + HCTZ | Hypertension | Film-coated tablets | 150/12.5, 300/12.5 and 300/25 mg |
| Ketorolac | Analgesic | Film-coated tablets | 10 mg |
| Lacosamide | Epilepsy | Oral solution | 10 mg/ml |
| Levetiracetam | Epilepsy | Film-coated tablets | 250, 500, 750 and 1000 mg |
| Levetiracetam | Epilepsy | Granules for oral solution | 250, 500, 750, 1000 and 1500 mg |
| Levetiracetam | Epilepsy | Oral solution | 100 mg/ml |
| Levomethadone ** | Pain, opiod maintenance therapy | Oral solution | 5 mg/ml |
| Levomethadone ** | Pain, opiod maintenance therapy | Oral drops, solution | 5 mg/ml |
| Lisinopril | Hypertension | Tablets | 5 and 20 mg |
| Lisinopril + HCTZ | Hypertension | Tablets | 20/12.5 mg |
| Loratadine | Allergy | Film-coated tablets | 10 mg |
[*] Differentiated product
[**] Opioid
Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.
© Neuraxpharm / LESVI. All rights reserved.